NB. Please note that if you are outside North America, the embargo for LANCET press material is 0001 hours UK Time 20 February 2004.
Results of a phase III study from Germany in this week'ss issue of THE LANCET suggest that a tumour-based vaccine could reduce disease recurrence and increase survival of patients who have had surgery for kidney cancer.
3% of cancer occurs in the kidney, with around 12,000 renal-cancer deaths a year in the USA. Removal of part or all of the kidney (nephrectomy) is the standard treatment for renal cancer, although other treatments after surgery (eg, radiotherapy, chemotherapy) are not effective. Around half of patients with renal cancer will have disease recurrence within 5 years.
Dieter Jocham from the University of Lubeck Medical School, Germany, and colleagues studied 558 patients from 55 medical centres in Germany with a renal tumour scheduled for nephrectomy. Before surgery, all patients were randomised to receive autologous renal tumour cell vaccine (six injections in the upper arm at 4-week intervals after surgery; the vaccine group) or no additional treatment (the control group).
Data were available for 379 patients. 5-year progression-free survival rates were 77% in the vaccine group and 68% in the control group. The vaccine was well tolerated, with only 12 adverse events associated with the treatment. The authors conclude that the vaccine can now be considered for renal cancer patients with tumours larger than 2.5 cm who have undergone nephrectomy.
Referring to Jocham and colleagues' study as an "immunological breakthrough", Mayer Fishman and Scott Antonia from H Lee Moffitt Cancer Center and Research Institute, Tampa, USA, state in an accompanying Commentary (p 583):"[Jocham and colleagues] carefully collected data are part of a broadening base of clinical observations of the potential to affect the biology of a solid tumour with non-toxic readministration of autologous tumour-derived materials. The key milestone is the suggestion of a fixed point-a non-toxic vaccine with a biological clinically relevant effect in T2-3N0 renal cancer-around which innovations can be built. Such a milestone can serve as a concrete step towards making adjuvant treatment of renal cancer a routine and effective intervention."
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
If you think you can do a thing or you think you can't do a thing, you're right.
-- Henry Ford